
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson is poised for future growth with a focus on high-growth platforms and shareholder returns, but challenges in certain areas could delay organic growth. The recent split to become a pure-play MedTech company and use of cash proceeds for shareholder returns show strong commitment to driving shareholder value. However, external factors and changes in healthcare delivery pose potential risks to long-term performance.
Bears say
Becton Dickinson is a global healthcare company focused on four business units, including medical essentials, connected care, biopharma systems, and interventional. The company has a negative outlook due to concerns over the impact of the COVID-19 pandemic and potential future headwinds in its core businesses. Despite strong diversity efforts and key initiatives in sustainability and environmental impact, Becton Dickinson may face challenges in achieving consistent MSD growth and its stock re-rating likely requires proof of this growth in the upcoming fiscal year.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares